- Home
- PIII vs AYTU Comparison
PIII vs AYTU Comparison
Compare PIII & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- AYTU
- Stock Information
- Founded
- PIII 2015
- AYTU N/A
- Country
- PIII United States
- AYTU United States
- Employees
- PIII N/A
- AYTU N/A
- Industry
- PIII Medical/Nursing Services
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- AYTU Health Care
- Exchange
- PIII Nasdaq
- AYTU Nasdaq
- Market Cap
- PIII 20.8M
- AYTU 19.7M
- IPO Year
- PIII N/A
- AYTU N/A
- Fundamental
- Price
- PIII $6.78
- AYTU $2.21
- Analyst Decision
- PIII Buy
- AYTU Strong Buy
- Analyst Count
- PIII 2
- AYTU 2
- Target Price
- PIII $16.25
- AYTU $10.00
- AVG Volume (30 Days)
- PIII 12.0K
- AYTU 140.9K
- Earning Date
- PIII 08-14-2025
- AYTU 09-25-2025
- Dividend Yield
- PIII N/A
- AYTU N/A
- EPS Growth
- PIII N/A
- AYTU N/A
- EPS
- PIII N/A
- AYTU N/A
- Revenue
- PIII $1,461,823,000.00
- AYTU $81,659,000.00
- Revenue This Year
- PIII N/A
- AYTU N/A
- Revenue Next Year
- PIII $7.92
- AYTU $1.05
- P/E Ratio
- PIII N/A
- AYTU $12.10
- Revenue Growth
- PIII 4.20
- AYTU 0.41
- 52 Week Low
- PIII $5.80
- AYTU $0.95
- 52 Week High
- PIII $30.50
- AYTU $2.85
- Technical
- Relative Strength Index (RSI)
- PIII 48.91
- AYTU 42.74
- Support Level
- PIII $6.42
- AYTU $2.15
- Resistance Level
- PIII $7.11
- AYTU $2.35
- Average True Range (ATR)
- PIII 0.55
- AYTU 0.15
- MACD
- PIII -0.03
- AYTU -0.05
- Stochastic Oscillator
- PIII 45.35
- AYTU 8.96
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.